Take a closer look at the progress of our first-in-class therapeutics.
| STAGE OF DEVELOPMENT | ||||||||
|---|---|---|---|---|---|---|---|---|
| Program | Indication PRURITUS |
Phase 1 | Phase 2 | Phase 3 | Approved | Commercial Rights | ||
|
KORSUVA™ injection1 |
HD-CKD | Commercial Rights: VFMCRP (ex-Japan and S. Korea)2,3 |
VFMCRP (ex-Japan
and S. Korea)2,3 |
|||||
| Oral difelikefalin |
Advanced NDD-CKD (stages IV-V) |
Commercial Rights: Cara Therapeutics |
Cara Therapeutics
|
|||||
| Oral difelikefalin | Atopic Dermatitis | Commercial Rights: Cara Therapeutics |
Cara
Therapeutics |
|||||
| Oral difelikefalin | Notalgia Paresthetica | Commercial Rights: Cara Therapeutics |
Cara Therapeutics
|
|||||
| Oral difelikefalin | Primary Biliary Cholangitis | Commercial Rights: Cara Therapeutics |
Cara Therapeutics
|
|||||
- 1. Approved in the EU and UK with the tradename Kapruvia™.
- 2. Commercialization rights to difelikefalin in defined indications – Japan: Maruishi Pharmaceutical Co, LTD; South Korea: Chong Kun Dang Pharmaceuticals.
- 3. Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has commercial rights under a profit-share arrangement in the US and a royalty arrangement ex-US.
HD-CKD: Hemodialysis Chronic Kidney Disease; NDD-CKD: Non-Dialysis Dependent Chronic Kidney Disease